Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab.

Manneh Kopp RA, Sepúlveda-Sánchez JM, Ruano Y, Toldos O, Pérez Núñez A, Cantero D, Hilario A, Ramos A, de Velasco G, Sánchez-Gómez P, Hernández-Laín A.

Clin Transl Oncol. 2019 Mar 15. doi: 10.1007/s12094-019-02070-6. [Epub ahead of print]

PMID:
30877636
2.

Correction to: SEOM clinical guideline for treatment of kidney cancer (2017).

Gallardo E, Méndez-Vidal MJ, Pérez-Gracia JL, Sepúlveda-Sánchez JM, Campayo M, Chirivella-González I, García-Del-Muro X, González-Del-Alba A, Grande E, Suárez C.

Clin Transl Oncol. 2019 May;21(5):692-693. doi: 10.1007/s12094-019-02058-2.

PMID:
30798511
3.

[Modal analysis of failures and effects in intra-hospital transfers].

Moya Suárez AB, Mora Banderas A, Fuentes Gómez V, Sepúlveda Sánchez JM, Canca Sánchez JC.

J Healthc Qual Res. 2019 Mar - Apr;34(2):66-77. doi: 10.1016/j.jhqr.2018.08.005. Epub 2019 Jan 8. Spanish.

PMID:
30635250
4.

Correction to: SEOM clinical guideline of diagnosis and management of low-grade glioma (2017).

Sepúlveda-Sánchez JM, Muñoz Langa J, Arráez MÁ, Fuster J, Hernández Laín A, Reynés G, Rodríguez González V, Vicente E, Vidal Denis M, Gallego Ó.

Clin Transl Oncol. 2018 Jan;20(1):108-109. doi: 10.1007/s12094-017-1814-z.

PMID:
29209952
5.

SEOM clinical guideline for treatment of kidney cancer (2017).

Gallardo E, Méndez-Vidal MJ, Pérez-Gracia JL, Sepúlveda-Sánchez JM, Campayo M, Chirivella-González I, García-Del-Muro X, González-Del-Alba A, Grande E, Suárez C.

Clin Transl Oncol. 2018 Jan;20(1):47-56. doi: 10.1007/s12094-017-1765-4. Epub 2017 Nov 13. Erratum in: Clin Transl Oncol. 2019 May;21(5):692-693.

6.

SEOM clinical guideline of diagnosis and management of low-grade glioma (2017).

Sepúlveda-Sánchez JM, Muñoz Langa J, Arráez MÁ, Fuster J, Hernández Laín A, Reynés G, Rodríguez González V, Vicente E, Vidal Denis M, Gallego Ó.

Clin Transl Oncol. 2018 Jan;20(1):3-15. doi: 10.1007/s12094-017-1790-3. Epub 2017 Nov 9. Erratum in: Clin Transl Oncol. 2017 Dec 5;:.

7.

Erratum: Efficacy and tolerability of lacosamide for secondary epileptic seizures in patients with brain tumor: A multicenter, observational retrospective study.

Sepúlveda-Sánchez JM, Conde-Moreno A, Barón M, Pardo J, Reynés G, Belenguer A.

Oncol Lett. 2017 Oct;14(4):4410. doi: 10.3892/ol.2017.6689. Epub 2017 Jul 28.

8.

Efficacy and tolerability of lacosamide for secondary epileptic seizures in patients with brain tumor: A multicenter, observational retrospective study.

Sepúlveda-Sánchez JM, Conde-Moreno A, Barón M, Pardo J, Reynés G, Belenguer A.

Oncol Lett. 2017 Jun;13(6):4093-4100. doi: 10.3892/ol.2017.5988. Epub 2017 Apr 5. Erratum in: Oncol Lett. 2017 Oct;14 (4):4410.

9.

Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.

Sepúlveda-Sánchez JM, Vaz MÁ, Balañá C, Gil-Gil M, Reynés G, Gallego Ó, Martínez-García M, Vicente E, Quindós M, Luque R, Ramos A, Ruano Y, Pérez-Segura P, Benavides M, Sánchez-Gómez P, Hernández-Laín A.

Neuro Oncol. 2017 Oct 19;19(11):1522-1531. doi: 10.1093/neuonc/nox105.

10.

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.

Capper D, von Deimling A, Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, Cher L, Steinbach JP, Specenier P, Rodon J, Cleverly A, Smith C, Gueorguieva I, Miles C, Guba SC, Desaiah D, Estrem ST, Lahn MM, Wick W.

Int J Mol Sci. 2017 May 6;18(5). pii: E995. doi: 10.3390/ijms18050995.

11.

Assessing motivation to smoking cessation in hospitalized patients.

Sepúlveda-Sánchez JM, Canca-Sánchez JC, Rivas-Ruiz F, Martín-García M, Lorente Márquez C, Timonet-Andreu EM.

Enferm Clin. 2018 Jan - Feb;28(1):13-19. doi: 10.1016/j.enfcli.2016.11.005. Epub 2017 Jan 7. English, Spanish.

PMID:
28073631
12.

New clinical trials regulation in Spain: analysis of royal decree 1090/2015.

Martin Jimenez M, Calvo Ferrandiz A, Aparicio Urtasun J, Garcia-Campelo R, Gonzalez-Flores E, Lazaro Quintela M, Muñoz Mateu M, Rodriguez Sanchez CA, Santaballa Bertran A, Sepulveda Sanchez JM, Vera Garcia R, Virizuela Echaburu JA, Segui Palmer MA.

Clin Transl Oncol. 2017 Mar;19(3):291-300. doi: 10.1007/s12094-016-1550-9. Epub 2016 Oct 7.

13.

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.

Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, Cher L, Steinbach JP, Capper D, Specenier P, Rodon J, Cleverly A, Smith C, Gueorguieva I, Miles C, Guba SC, Desaiah D, Lahn MM, Wick W.

Neuro Oncol. 2016 Aug;18(8):1146-56. doi: 10.1093/neuonc/now009. Epub 2016 Feb 21.

14.

[Pain management nursing in hospitalized patients with non-oncological diseases].

Sepúlveda-Sánchez JM, Canca-Sánchez JC, Rivas-Ruiz F, Martín-García M, Pérez-González MJ, Timonet-Andreu EM.

Enferm Clin. 2016 Mar-Apr;26(2):137-41. doi: 10.1016/j.enfcli.2015.09.002. Epub 2015 Nov 15. Spanish.

PMID:
26589775
15.

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.

Rodón J, Carducci M, Sepulveda-Sánchez JM, Azaro A, Calvo E, Seoane J, Braña I, Sicart E, Gueorguieva I, Cleverly A, Pillay NS, Desaiah D, Estrem ST, Paz-Ares L, Holdhoff M, Blakeley J, Lahn MM, Baselga J.

Invest New Drugs. 2015 Apr;33(2):357-70. doi: 10.1007/s10637-014-0192-4. Epub 2014 Dec 23.

16.

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study.

Kovacs RJ, Maldonado G, Azaro A, Fernández MS, Romero FL, Sepulveda-Sánchez JM, Corretti M, Carducci M, Dolan M, Gueorguieva I, Cleverly AL, Pillay NS, Baselga J, Lahn MM.

Cardiovasc Toxicol. 2015 Oct;15(4):309-23. doi: 10.1007/s12012-014-9297-4.

17.

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma.

Rodon J, Carducci MA, Sepulveda-Sánchez JM, Azaro A, Calvo E, Seoane J, Braña I, Sicart E, Gueorguieva I, Cleverly AL, Pillay NS, Desaiah D, Estrem ST, Paz-Ares L, Holdhoff M, Blakeley J, Lahn MM, Baselga J.

Clin Cancer Res. 2015 Feb 1;21(3):553-60. doi: 10.1158/1078-0432.CCR-14-1380. Epub 2014 Nov 25.

18.

Impact of a legislative framework on quality of end-of-life care and dying in an acute hospital in Spain.

Sepúlveda Sánchez JM, Canca Sánchez JC, Pérez Trueba E, Rueda Dominguez A, Morales Asencio JM, Morales Gil IM.

Int J Palliat Nurs. 2014 May;20(5):225-31.

PMID:
24852029
19.

[The right to die with dignity in an acute-care hospital: a qualitative study].

Sepúlveda-Sánchez JM, Morales-Asencio JM, Morales-Gil IM, Canca-Sánchez JC, Crespillo-García E, Timonet-Andreu EM.

Enferm Clin. 2014 Jul-Aug;24(4):211-8. doi: 10.1016/j.enfcli.2014.03.004. Epub 2014 Apr 26. Spanish.

PMID:
24775466
20.

Classification of oligodendroglial tumors based on histopathology criteria is a significant predictor of survival--clinical, radiological and pathologic long-term follow-up analysis.

Sepulveda Sanchez JM, Martinez Montero JC, Diez-Lobato R, Hernandez-Lain A, Cabello A, Ramos A, Gonzalez Leon P, Ricoy Campo JR.

Clin Neuropathol. 2009 Jan-Feb;28(1):11-20. Erratum in: Clin Neuropathol. 2009 Mar-Apr;28(2):150.

PMID:
19216215
21.

[Temporal lobe epilepsy. Aetiological classification in 61 paediatric patients].

González de la Aleja Tejera J, Sepúlveda Sánchez JM, Simón de las Heras R, Muñoz González A, Saiz Díaz RA, Rodríguez Peña-Marín M, Camacho Salas A, Mateos Beato F.

An Pediatr (Barc). 2008 Sep;69(3):227-31. Spanish.

22.

[The pathophysiology of migraine. Reflections on the glutamatergic hypothesis].

Gonzalez de la Aleja J, Porta-Etessam J, Sepulveda-Sanchez JM, Rodriguez Pena-Marin M.

Rev Neurol. 2006 Oct 16-31;43(8):481-8. Review. Spanish.

23.

[Topiramate in comorbid disorders: epilepsy and migraine].

Dorado R, Gómez-Arguelles JM, Herrera A, Aragón E, Blanco M, Gilo-Arrojo F, Sepúlveda-Sánchez JM, González de la Aleja J, Anciones B.

Rev Neurol. 2006 Aug 16-31;43(4):193-6. Spanish.

24.

[Sarcoid myopathy. Report of two cases and review of the bibliography].

Sepúlveda-Sánchez JM, Villarejo-Galende A, Cabello A, Alonso-Ortiz A, Ibero-Esparza C, Porta-Etessam J.

Rev Neurol. 2005 Aug 1-15;41(3):159-62. Spanish.

25.

[Adult-onset subacute sclerosing panencephalitis: clinicopathological findings].

González de la Aleja J, Posada IJ, Sepúlveda-Sánchez JM, Galán L, Conde-Gallego E, Ricoy-Campo JR.

Rev Neurol. 2005 Jun 16-30;40(12):729-32. Spanish.

26.

[Homocysteine and cerebrovascular disease].

Sepúlveda-Sánchez JM, Matía-Francés R, Martínez-Salio A, González-de la Aleja-Tejera J, Rodríguez-Peña Marín M, Porta-Etessam J.

Rev Neurol. 2004 Feb 16-29;38(4):347-58. Review. Spanish.

Supplemental Content

Loading ...
Support Center